HORIZONS



Understanding the impact of cancer diagnosis and treatment on everyday life

6 MONTH CERVICAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the baseline CRF when completing this 6 month CRF: the questions marked with a RED ASTERISK need only be answered if they were marked "not currently known", "unknown" or left blank at baseline
- If you have any queries, please contact the HORIZONS Coordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

Participant's Study ID				
Participant's date of birth	d d m m y y y y			
Participant's tumour type (pwas answered at baseline)*	please tick one box below, or tick to indicate the question			
This question was answered	at baseline			
Туре	Sub-type			
Cervical	Squamous cell carcinoma			
	Adenosquamous carcinoma			
	Clear cell carcinoma			
	Other (please describe on line below)			
	Not currently known			
Date of participant's current question was answered at ba	cancer diagnosis (please add details or tick to indicate the aseline)*			
This question was answered at baseline				
Tills question was answered	at baseline			
Date of current cancer diagn	nosis			
(date that histological diagnosis was reported)				

Participant ^e	's Study ID		/		
·	c's FIGO stage at vas answered at		ease tick one	e box OR tio	ck to indicate the
This questi	ion was answere	ed at baseline			
Stage 1	Stage IA2				
	Stage IB1			IMPORTAN	IT—YOU SHOULD HAVE
	Stage IB2				A FIGO STAGING FOR
Stage 2	Stage 2A1				FICIPANT, EITHER IN THIS THE BASELINE CRF
	Stage 2A2				
	Stage 2B				
Stage 3	Stage 3A				
	Stage 3B				
question wa	s tumour grade as answered at k on was answere	paseline)*	ne box OR ti	ck to indicat	te the
Grade 1/lov	v grade/well diff	ferentiated			
Grade 2/mc	oderate/interme	ediate grade			
Grade 3/hig	h-grade/poorly	differentiated			
Grade not c	urrently known				

Participant's Study ID / / /		
Has the participant had any other genetic to box)	tests for inherited cancers? (pleas	e tick one
Yes (already recorded in baseline CRF)		
Yes (but not recorded in baseline CRF)		
No		
Unknown		
If you answered "Yes (but not recorded in provide some information about the particular the table(s) below	•	-
Name of genetic test for cancer (1)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	
Name of genetic test for cancer (2)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	

Participant's Study ID / /	
Has the participant developed any NEW co-morbidities (which were not reed in the baseline CRF)? (please tick all that apply) in the tables below and leaf)	
Myocardial infarct	
Angina/coronary artery disease	
Congestive Heart Failure	
Cardiac Arrythmias	
Hypertension	
Venous Disease (PE/DVT)	
Peripheral Arterial Disease	
Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)	
Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	

Participant's new co-morbidities continued	
Clinical diagnosis of depression	
Psychiatric Diagnosis (eg. schizophrenia, bipolar disorder)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder, polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	

Participant's Study ID

Participant's Study ID]/[/	
------------------------	--	-----	--	----------	--

What was the participant's route to diagnosis (the route they took through the healthcare system before receiving a cancer diagnosis)? (please tick one box)

The participant was diagnosed:	
1. Following attendance at a screening programme (via the national screen-	
ing programmes for bowel, breast and cervical cancers)	
2. During/following a hospital outpatient appointment which resulted from:	
i) An urgent GP referral for suspected cancer ("Two-week wait")	
ii) A routine GP referral (for symptoms which don't arouse suspicion of can-	
cer but need investigating)	
iii) A referral from a different outpatient specialty (eg. ENT)	
3. During/following an admission to hospital which was:	
i) An inpatient elective	
ii) An emergency (after an emergency GP referral, during an A&E visit, whilst	
in hospital due to an emergency)	
4. Other (please give details)	
5. Unknown	

Double in a set/a Ctural LID	
Participant's Study ID	

What treatments has the participant received, please tick ALL that apply and write details in the spaces provided

Treatment/ other pro- cedure	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Neo-adjuvant chemotherapy	CarboTaxol (paclitaxel and carboplatin)		// 20	// 20	
Diagnostic pro- cedure	LLETZ/Cone biopsy		// 20		
Surgery	Abdominal total hysterectomy		// 20		
	Laparoscopic total hysterectomy		// 20		
	Abdominal radical hysterectomy		// 20		
	Laparoscopic radical hysterectomy		// 20		
	Radical trachelectomy		// 20		
	Lymphadenectomy		// 20		
	Other surgery (please describe)		// 20		
Adjuvant or stand alone	CHEMOTHERAPY = Cisplatin		// 20	// 20	
chemo radia- tion	CHEMOTHERAPY = CarboTaxol (paclitaxel and carboplatin)		// 20	// 20	
(please give details for chemo-	CHEMOTHERAPY = Other (please describe)		// 20	// 20	
therapy AND radio- therapy overleaf)	Chemotherapy number of cycles(J	olease ent	er on line)		

Participant's Study ID	

Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Combined external radio- therapy and brachytherapy		// 20	// 20	
External radiotherapy		//20	// 20	
Number of radiotherapy f	ractions (ple	ase enter on line)		
Dose for each radiotherapy	y fraction (pl	ease enter on line)		
Intrauterine Image Guided- Brachytherapy (IGBT)		// 20	//20	
Number of radiotherapy fr	actions (plea	ase enter on line)		
Dose for each radiotherapy	fraction (ple	ease enter on line)		
Were interstitial needles used? (please tick one)	Yes	No	0	
Intravaginal Image Guided- Brachytherapy (IGBT)		// 20	//20	
Number of radiotherapy fr	ractions (ple	ase enter on line)		
Dose for each radiotherap	y fraction (p	lease enter on line)		
Were interstitial needles used? (please tick one)	Yes	No	0	

Participant's Study ID / /				
Is the participant taking part in a clinical tri	al? (please tick one box)			
Yes No	Unknown			
If you answered "yes" to the above question cal trial the participant is taking part in	on, please give the NAME of the clini-			
Name of clinical trial				
Since the participant's diagnosis of cervica another new primary cancer? (please tick	•			
Yes No Unknown				
If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table overleaf				
Details of participant's new cancer diagnosis				
Type of cancer				
Date of diagnosis	// 20			
Treatment received	4 400			
Date treatment ended (if finished)	// 20			

Participant's Study ID / /
Has the participant had a recurrence of their cervical cancer? (please tick one box)
Yes No
If the participant has had a recurrence, on what date was the recurrence
diagnosed? d d m m y y y y
If the participant has had a recurrence, was the recurrence local or distant? (please
tick one box)
Local recurrence
Distant recurrence
If the participant has had a recurrence, is any further treatment planned? (please
tick one box and if "yes" give details)
Yes No
Please describe any planned treatment

Participant's Study ID / / / / / / / / / / / / / / / / / /	
What type of follow-up care is the participant receiving? (please tick ONE bo	x)
Routine/regular hospital clinic based follow-up (medical or nurse led, face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?	

Has the participant been referred to any of the following services and/or had a Holistic Needs Assessment? (please tick all that apply)

Participant has been referred to palliative care services	
Participant has been referred to psychological services	
Participant has been referred to community services	
Participant has had an HNA (holistic needs assessment)	

If the participant has died please give the date and cause of death: Participant's date of death Cause of participant's death 1) a) 1) b) 1) c) 2) Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Date CRF completed Date CRF completed Date CRF completed Date Triple Act and Cause of death: Participant's date of death: Date CRF completed Date CRF completed	Participant's Study ID / /
Participant's date of death Cause of participant's death 1) a) 1) b) 1) c) 2) Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Signature	
Participant's date of death Cause of participant's death 1) a) 1) b) 1) c) 2) Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Signature	
Cause of participant's death 1) a) 1) b) 1) c) 2) Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature	If the participant has died please give the date and cause of death:
1) a) 1) b) 1) c) 2) Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature	
1) b) 1) c) 2) Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Date CRE completed	Cause of participant's death
Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Date CRE completed	1) a)
Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Date CRE completed	1) b)
Cause of death not known Please add your name and signature and the date that you completed this CRF Name Signature Date CRE completed	1) c)
Please add your name and signature and the date that you completed this CRF Name Signature	2)
Name Signature	Cause of death not known
Date CRE completed	Please add your name and signature and the date that you completed this CRF
Date CRE completed	Name Signature
	Date CRF completed